Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (DE:0K4)
BERLIN:0K4
RESEARCH TOOLSreports
Akero Therapeutics (0K4) Stock Price & Analysis
2 Followers
0K4 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.80 - €55.00
Previous Close€19.05
Volume0.00
Average Volume (3M)160.00
Market Cap
€1.35B
Enterprise Value€835.87M
Total Cash (Recent Filing)$550.01M
Total Debt (Recent Filing)$25.78M
Price to Earnings (P/E)N/A
Beta-0.65
Next Earnings
May 14, 2024EPS Estimate
-€0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding56,297,528
10 Day Avg. Volume0
30 Day Avg. Volume160
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.31
Forecast
1Y Price Target
€47.70Price Target Upside150.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Akero Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAkero's 96-week data from the Phase IIb HARMONY trial showed unprecedented improvements in liver fibrosis, indicating potential efficacy of their drug for F2-F3 NASH patients.
Financial PositionAkero ends the financial year with a robust cash balance, enhanced by equity financing, positioning the company strongly for future operations and investment.
Regulatory MilestonesA successful End-of-Phase 2 meeting with the FDA marks a pivotal moment for Akero, potentially accelerating the pathway for their lead drug candidate in treating metabolic dysfunction-associated steatohepatitis.
Bears Say
Clinical Trial ResultsEfruxifermin (EFX) failed to meet the primary endpoint of fibrosis improvement versus placebo after 36 weeks of treatment in the SYMMETRY trial for cirrhotic NASH patients.
Regulatory ChallengesThe failure of the SYMMETRY study to provide evidence of fibrosis improvement in cirrhotics may complicate the regulatory path forward with the FDA for Phase 3 trials.
Safety And TolerabilityConcerns have been raised about the rates of nausea and diarrhea at the higher EFX dose that may affect patient adherence to the treatment.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
0K4 FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was €10.80 and its highest was €55.00 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is May 14, 2024 which is in 20 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Feb 29, 2024. The company reported -€0.933 earnings per share for the quarter, missing the consensus estimate of -€0.78 by -€0.153.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -€0.89.
How many shares outstanding does Akero Therapeutics Inc have?
Currently, no data Available
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -€0.933 in its last earnings report, missing expectations of -€0.78. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Akero Therapeutics Inc’s shares valued at 55M.
---
Akero Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€47.70 (150.39% Upside)
€47.70 (150.39% Upside)
Blogger Sentiment
Bullish
DE:0K4 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $115.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.93%
12-Months-Change
Fundamentals
Return on Equity
-35.22%
Trailing 12-Months
Asset Growth
62.74%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
0K4 Stock 12 Months Forecast
Average Price Target
€47.70
▲(150.39% Upside)
Technical Analysis
Akero Therapeutics
―
MacroGenics
―
Alector
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 0K4
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-7.77%
reiterated a buy rating 2 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -7.77% per trade.
---